Gujarat Themis Biosyn quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	43.8	35.9	+22.1%
EBITDA	20.8	13.9	+49.4%
EBITDA margin	47.5%	38.8%	+8.7 pts
Profit before tax	15.2	12.1	+25.1%
Net profit	11.1	9.1	+22.1%
EPS	₹1.02	₹0.83	+22.9%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025

Expenses
	43.8	44.2	43.4	42.3	35.9	37.7
	0.1	0.9	0.4	0.8	0.3	1.3
	43.9	45.2	43.8	43.2	36.1	39.1
	7.7	10.1	6.6	6.9	6.8	6.9
	−3.9	−6.5	−0.8	−1.5	−0.2	−0.6
	4.7	3.8	4.8	4.8	3.1	3.1
	1.8	1.9	1.0	0.0	0.0	0.1
	4.0	4.0	3.9	3.0	2.0	1.2
	14.5	17.5	11.5	11.2	12.2	12.3
	28.8	30.8	26.9	24.4	24.0	23.0
	20.8	19.4	21.3	20.9	13.9	16.0
	16.8	15.3	17.4	18.0	11.9	14.8
Profit
	15.2	14.3	16.9	18.8	12.1	16.1
	15.2	14.3	16.9	18.8	12.1	16.1
	2.7	2.4	2.9	3.1	2.5	3.9
	1.4	1.1	1.5	1.4	0.6	0.2
	4.1	3.4	4.4	4.5	3.1	4.1
	11.1	10.9	12.5	14.3	9.1	12.0
	11.1	10.9	12.5	14.3	9.1	12.0
	0.0	0.0	0.0	0.0	0.0	0.1
	11.1	10.9	12.5	14.3	9.1	12.1
Per share
	₹1.02	₹1.00	₹1.14	₹1.31	₹0.83	₹1.10
	₹1.02	₹1.00	₹1.14	₹1.31	₹0.83	₹1.10
Other comprehensive income — detail
	0.0	0.0	0.0	0.0	0.0	0.1
	—	0.0	0.0	0.0	0.0	0.1
	−0.0	0.0	0.0	0.0	0.0	0.0
Per share — as-filed variants
	₹1.02	₹1.00	₹1.14	₹1.31	₹0.83	₹1.10
	₹1.02	₹1.00	₹1.14	₹1.31	₹0.83	₹1.10
Regulatory disclosures — filed alongside, not part of the P&L
	—	9.7	—	0.5	—	0.5
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	40.0	40.7	37.5	37.0	29.2	31.5
	91.3%	92.0%	86.6%	87.3%	81.5%	83.5%
Adjusted (ex-exceptional items) — derived
	15.2	14.3	16.9	18.8	12.1	16.1
	11.1	10.9	12.5	14.3	9.1	12.0
	₹1.02	₹1.00	₹1.14	₹1.31	₹0.83	₹1.10

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

GUJTHEM₹355.55

Gujarat Themis Biosyn Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersRPGLIFE GUFICBIO ORCHPHARMA UNICHEMLAB FDC IOLCP MOREPENLAB INNOVACAPMcap ₹3,874 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	37.7	35.9	42.3	43.4	44.2	43.8
Other Income	1.3	0.3	0.8	0.4	0.9	0.1
Total Income	39.1	36.1	43.2	43.8	45.2	43.9
Expenses
+ Cost of Materials Consumed	6.9	6.8	6.9	6.6	10.1	7.7
+ Changes in Inventories	-0.6	-0.2	-1.5	-0.8	-6.5	-3.9
+ Employee Benefit Expense	3.1	3.1	4.8	4.8	3.8	4.7
+ Finance Costs	0.1	0.0	0.0	1.0	1.9	1.8
+ Depreciation & Amortisation	1.2	2.0	3.0	3.9	4.0	4.0
+ Other Expenses	12.3	12.2	11.2	11.5	17.5	14.5
Total Expenses	23.0	24.0	24.4	26.9	30.8	28.8
EBITDA	16.0	13.9	20.9	21.3	19.4	20.8
EBIT	14.8	11.9	18.0	17.4	15.3	16.8
Profit
PBT before Exceptional Items	16.1	12.1	18.8	16.9	14.3	15.2
Pretax Income	16.1	12.1	18.8	16.9	14.3	15.2
+ Current Tax	3.9	2.5	3.1	2.9	2.4	2.7
+ Deferred Tax	0.2	0.6	1.4	1.5	1.1	1.4
Tax Expense	4.1	3.1	4.5	4.4	3.4	4.1
Net Income	12.0	9.1	14.3	12.5	10.9	11.1
+ Net Income — Continuing Ops	12.0	9.1	14.3	12.5	10.9	11.1
+ Other Comprehensive Income	0.1	0.0	0.0	0.0	0.0	0.0
Total Comprehensive Income	12.1	9.1	14.3	12.5	10.9	11.1
Per Share
Basic EPS	1.10	0.83	1.31	1.14	1.00	1.02
Diluted EPS	1.10	0.83	1.31	1.14	1.00	1.02
Other Comprehensive Income — detail
+ Other Comprehensive Income	0.1	0.0	0.0	0.0	0.0	0.0
+ Items NOT to be Reclassified to P&L	0.1	0.0	0.0	0.0	0.0	—
+ Tax on Items NOT to be Reclassified	0.0	0.0	0.0	0.0	0.0	-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	1.10	0.83	1.31	1.14	1.00	1.02
Diluted EPS — Continuing Operations	1.10	0.83	1.31	1.14	1.00	1.02
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	0.5	—	0.5	—	9.7	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	31.5	29.2	37.0	37.5	40.7	40.0
Gross Margin %	83.50	81.53	87.26	86.57	91.96	91.28
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	16.1	12.1	18.8	16.9	14.3	15.2
Net Income Adj (tax-effected)	12.0	9.1	14.3	12.5	10.9	11.1
EPS Adj	1.10	0.83	1.31	1.14	1.00	1.02
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	—	1.00	1.00	1.00	1.00
Paid Up Equity Capital	10.9	10.9	10.9	10.9	10.9	10.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Gujarat Themis Biosyn Q2 FY27 results date

Gujarat Themis Biosyn (NSE: GUJTHEM) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 27 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹11.1 crore, up 22.1% from ₹9.1 crore in Q1 FY26 and up 1.6% from ₹10.9 crore in Q4 FY26. Revenue from operations was ₹43.8 crore, up 22.1% year on year and down 1.0% from the previous quarter.

Board-meeting notice filed: 27 October 2026
Q2 FY26 results (a year earlier): 10 November 2025
Q1 FY27 results (the latest): 7 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 27 Oct
Q1 FY27 net profit: ₹11.1 Cr+22.1% vs Q1 FY26+1.6% vs Q4 FY26
Q1 FY27 revenue: ₹43.8 Cr+22.1% vs Q1 FY26−1.0% vs Q4 FY26
Q1 FY27 operating margin: 38.4%+5.3 pts vs Q1 FY26+3.8 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹14.3 CrRevenue ₹42.3 Cr
Q1 FY27 EPS (basic): ₹1.02

Questions

When will Gujarat Themis Biosyn announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 27 October 2026). Last year it reported Q2 FY26 on 10 November 2025.

What will Gujarat Themis Biosyn's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹14.3 crore and revenue from operations ₹42.3 crore. The latest quarter, Q1 FY27, had a net profit of ₹11.1 crore and revenue of ₹43.8 crore.

What were Gujarat Themis Biosyn's Q1 FY27 results?

Consolidated net profit was ₹11.1 crore, up 22.1% from ₹9.1 crore in Q1 FY26 and up 1.6% from ₹10.9 crore in Q4 FY26. Revenue from operations was ₹43.8 crore, up 22.1% year on year and down 1.0% from the previous quarter.

How has Gujarat Themis Biosyn's profit changed over the last four quarters?

Net profit by quarter: ₹14.3 crore in Q2 FY26, ₹12.5 crore in Q3 FY26, ₹10.9 crore in Q4 FY26 and ₹11.1 crore in Q1 FY27. That is ₹48.7 crore over the four quarters. Revenue from operations: ₹42.3 crore, ₹43.4 crore, ₹44.2 crore and ₹43.8 crore.

What was Gujarat Themis Biosyn's net profit in FY26?

Consolidated net profit was ₹46.7 crore in FY26 (April 2025–March 2026), down 4.3% from ₹48.8 crore in FY25.

What was Gujarat Themis Biosyn's revenue in FY26?

Revenue from operations was ₹166 crore in FY26 (April 2025–March 2026), up 10.0% from ₹151 crore in FY25.

Where do these Gujarat Themis Biosyn figures come from?

From Gujarat Themis Biosyn's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.